Literature DB >> 23387866

Eczema herpeticum with herpetic folliculitis after bone marrow transplant under prophylactic acyclovir: are patients with underlying dermatologic disorders at higher risk?

J M Mir-Bonafé1, C Román-Curto, A Santos-Briz, I Palacios-Álvarez, J C Santos-Durán, E Fernández-López.   

Abstract

We present an unreported coexistence: eczema herpeticum (EH) with histopathological findings of herpetic folliculitis (HF) after allogeneic bone marrow transplantation (BMT). A patient with atopic dermatitis (AD) underwent allogeneic BMT for idiopathic acquired aplastic anemia. She had been receiving cyclosporine (150 mg/12 h) and acyclovir (400 mg/12 h) for 6 months. A facial rash was observed, composed of monotonous erythematous, umbilicated papulo-vesicles and papulo-crusts <4 mm in size. The histopathological study showed herpetic cytopathic changes within the epidermis that extended into the hair follicle epithelium. Interestingly, microscopic HF has not previously been associated with post-transplant patients or EH. However, it is reasonable to hypothesize that the coexistence of these herpes simplex virus-related events may be underreported in the literature. Although further studies are necessary, we suggest that the prophylactic antiviral dose after BMT be enhanced in patients with underlying dermatologic diseases, especially in those with AD.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23387866     DOI: 10.1111/tid.12058

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  2 in total

1.  Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity.

Authors:  Imir G Metushi; Amanda Wriston; Priyanka Banerjee; Bjoern Oliver Gohlke; A Michelle English; Andrew Lucas; Carrie Moore; John Sidney; Soren Buus; David A Ostrov; Simon Mallal; Elizabeth Phillips; Jeffrey Shabanowitz; Donald F Hunt; Robert Preissner; Bjoern Peters
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

2.  Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking.

Authors:  George Van Den Driessche; Denis Fourches
Journal:  J Cheminform       Date:  2018-01-30       Impact factor: 5.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.